Repligen Corporation (NasdaqGS:RGEN) agreed to acquire Avitide, Inc. for approximately $280 million on September 16, 2021. $75 million in cash plus $75 million in Repligen common stock in addition to performance-based earnout payments over the next three years. To fund the transaction, Repligen intends to use its cash on hand, which totaled approximately $734 million at June 30, 2021. Avitide had revenues of $2.5 million in financial year 2020. The transaction is expected to be completed during the third quarter of 2021, subject to the satisfaction of customary closing conditions. The transaction is expected to be accretive to Repligen?s adjusted earnings per share in 2023. Perella Weinberg Partners (NasdaqGS:PWP) acted as financial advisor to Repligen Corporation. Goodwin Procter LLP acted as legal advisor to Repligen Corporation. Evan S. Yellin, David Zimbalist, Gerard Toohey, Ralph Bonavitacola and Matthew Nicastro of EC Mergers & Acquisitions acted as financial advisors to Avitide, Inc. Mark Stein and Mark Opitz of Morgan, Lewis & Bockius LLP acted as legal advisor to Avitide, Inc.